These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30971509)

  • 1. Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.
    Boo YL; Liam CCK; Toh SG; Lim SM
    Hong Kong Med J; 2019 Apr; 25(2):162-163. PubMed ID: 30971509
    [No Abstract]   [Full Text] [Related]  

  • 2. Ponatinib (Iclusig) for CML and Ph+ ALL.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
    [No Abstract]   [Full Text] [Related]  

  • 3. Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
    Shomali W; Redmond C; Bogati S; Zimmerman C; Visconte V; Tabarroki A; Kalaycio M; Tiu RV
    Leuk Lymphoma; 2016; 57(1):193-5. PubMed ID: 25942382
    [No Abstract]   [Full Text] [Related]  

  • 4. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib superior to imatinib in Ph
    Sidaway P
    Nat Rev Clin Oncol; 2024 Jul; 21(7):483. PubMed ID: 38806653
    [No Abstract]   [Full Text] [Related]  

  • 6. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
    Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
    Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
    [No Abstract]   [Full Text] [Related]  

  • 7. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
    Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
    Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponatinib-induced neutrophilic panniculitis.
    Zhang M; Hassan KM; Musiek A; Rosman IS
    J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-drug discovery and cardiovascular surveillance.
    Groarke JD; Cheng S; Moslehi J
    N Engl J Med; 2013 Nov; 369(19):1779-81. PubMed ID: 24180496
    [No Abstract]   [Full Text] [Related]  

  • 11. Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation.
    Goodrich AD
    Expert Rev Hematol; 2014 Oct; 7(5):513-5. PubMed ID: 25199408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.
    Shacham-Abulafia A; Raanani P; Lavie D; Volchek Y; Ram R; Helman I; Shargian L; Gourevitch A; Chubar E; Ratzon R; Rozovski U
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e295-e301. PubMed ID: 29773429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors.
    Santoro M; Accurso V; Mancuso S; Contrino AD; Sardo M; Novo G; Di Piazza F; Perez A; Russo A; Siragusa S
    Chemotherapy; 2019; 64(4):205-209. PubMed ID: 31825920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL1 compound mutations drive ponatinib resistance.
    Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib in Philadelphia chromosome-positive leukemias.
    Quintas-Cardama A
    N Engl J Med; 2014 Feb; 370(6):577. PubMed ID: 24499222
    [No Abstract]   [Full Text] [Related]  

  • 16. Success is built on failures: tackling the challenge of ponatinib failure.
    Hiwase D; Ross D
    Leuk Lymphoma; 2018 Jun; 59(6):1279-1281. PubMed ID: 29382246
    [No Abstract]   [Full Text] [Related]  

  • 17. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia.
    Engel NW; Constantin A; Fowlkes S; Assouline S
    J Oncol Pract; 2016 Jun; 12(6):592-4. PubMed ID: 27246687
    [No Abstract]   [Full Text] [Related]  

  • 18. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.
    Hamadi A; Grigg AP; Dobie G; Burbury KL; Schwarer AP; Kwa FA; Jackson DE
    Thromb Haemost; 2019 Jul; 119(7):1112-1123. PubMed ID: 31079415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.
    Breccia M; Abruzzese E; Iurlo A; Gozzini A; Isidori A; Gangemi D; Pregno P; Alimena G
    Haematologica; 2016 Jun; 101(6):e267-8. PubMed ID: 27252515
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.
    Andrews C; Lipton J
    Leuk Lymphoma; 2019 Dec; 60(13):3099-3101. PubMed ID: 31556337
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.